Maximum Tolerated Dose, Safety and Pharmacologic Study of TRF in Women With Breast Cancer
Phase Ib: Maximum Tolerated Dose, Safety and Pharmacologic Study of TRF in Women with Breast Cancer is aimed to determine the highest, safest and tolerable dose of Tocotrienol-rich Fraction (maximal tolerated dose: MTD) that can be used in women with breast cancer.
Breast Cancer Female
DIETARY_SUPPLEMENT: Tocotrienol-rich Fraction (TRF)
Physical Assessment, Number of participants with treatment-related adverse events as assessed by CTCAE version 5.0, For 2 to 4 weeks during supplementation|Liver Function Test, Liver enzymes with units of U/L, For 2 to 4 weeks during supplementation
Bioavailability of TRF, Blood pharmacokinetic parameters, For 2 to 4 weeks during supplementation
3+3 step up design method will be used in this study.